Efficacy and Safety of Rituximab Therapy to Sustain Remission in Young Children With Childhood Nephrotic Syndrome.

70 older children), although insignificant, younger children showed a trend toward earlier relapse (8.3 vs. 11.3 months; log-rank test P = 0.14), and more complications (hypogammaglobulinemia, 63% vs. 35%; P = 0.01; neutropenia, 13% vs. 7%; infection, 9% vs. 4%).

also in 53,322 other papers

5%) were also higher, although these differences did not reach statistical significance.

also in 111,027 other papers